Clinical efficacy of recombinant versus highly purified follicle-stimulating hormone according to follicle-stimulating hormone receptor genotype

Pharmacogenetics and Genomics

Volumn 26, Issue 6, 2016, Pages 288-293

  Lledó, Belén ^a   Dapena, Patricia ^a   Ortiz, Jose A ^a   Morales, Ruth ^a   Llacer, Joaquín ^b   Bernabeu, Rafael ^a,b  

^a Departmento Biol Molecular   (Spain)

^b Instituto Bernabeu of Fertility and Gynecology   (Spain)

Author keywords

Controlled ovarian hyperstimulation; follicle stimulating hormone receptor; N680S; single nucleotide polymorphisms

Indexed keywords

CETRORELIX; FOLLITROPIN; FOLLITROPIN RECEPTOR; HIGHLY PURIFIED FOLLICLE STIMULATING HORMONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN; UNCLASSIFIED DRUG; HORMONE; RECOMBINANT PROTEIN;

ADD ON THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; DONOR; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; METAPHASE; OOCYTE; OOCYTE MATURATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; OVULATION INDUCTION; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; GENOTYPE; HORMONES; HUMANS; OOCYTES; OVULATION INDUCTION; POLYMORPHISM, GENETIC; RECEPTORS, FSH; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960193689     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000215     Document Type: Article

References (30)

1. Dupakuntla M, Mahale SD. Accessibility of the extracellular loops of follicle stimulating hormone receptor and their role in hormone-receptor interaction. Mol Cell Endocrinol 2010; 315:131-137.
2. Oehninger S. Ovulation induction in IVF. Minerva Ginecol 2011; 63:137-156.
3. Kligman I, Rosenwaks Z. Differentiating clinical profiles: Predicting good responders, poor responders, and hyperresponders. Fertil Steril 2001; 76:1185-1190.
4. Coccia ME, Rizzello F. Ovarian reserve. Ann N Y Acad Sci 2008; 1127:27-30.
5. Haller K, Salumets A, Uibo R. Anti-FSH antibodies associate with poor outcome of ovarian stimulation in IVF. Reprod Biomed Online 2008; 16:350-355.
6. Mutsatsa S, Currid TJ. Pharmacogenetics: A reality or misplaced optimism? J Psychiatr Ment Health Nurs 2013; 20:314-320.
7. Fauser BC, Diedrich K, Devroey P. Predictors of ovarian response: Progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 2008; 14:1-14.
8. Simoni M, Tempfer CB, Destenaves B, Fauser BC. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Hum Reprod Update 2008; 14:459-484.
9. Altmäe S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: Where do we stand today? Hum Reprod Update 2011; 17:813-828.
10. Yao Y, Ma CH, Tang HL, Hu YF. Influence of follicle-stimulating hormone receptor (FSHR) Ser680Asn polymorphism on ovarian function and in-vitro fertilization outcome: A meta-analysis. Mol Genet Metab 2011; 103:388-393.
11. Laan M, Grigorova M, Huhtaniemi IT. Pharmacogenetics of follicle-stimulating hormone action. Curr Opin Endocrinol Diabetes Obes 2012; 19:220-227.
12. Lledo B, Guerrero J, Turienzo A, Ortiz JA, Morales R, Ten J, et al. Effect of follicle-stimulating hormone receptor N680S polymorphism on the efficacy of follicle-stimulating hormone stimulation on donor ovarian response. Pharmacogenet Genomics 2013; 23:262-268.
13. Huang X, Li L, Hong L, Zhou W, Shi H, Zhang H, et al. The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation. Clin Endocrinol (Oxf) 2015; 82:577-583.
14. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85:3365-3369.
15. Van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van Der Veen F, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011; 2: CD005354.
16. Wide L, Eriksson K, Sluss PM, Hall JE. Serum half-life of pituitary gonadotropins is decreased by sulfonation and increased by sialylation in women. J Clin Endocrinol Metab 2009; 94:958-964.
17. Andersen CY, Westergaard LG, Van Wely M. FSH isoform composition of commercial gonadotrophin preparations: A neglected aspect? Reprod Biomed Online 2004; 9:231-236.
18. Andersen CY, Ezcurra D. What is the clinical relevance of follicle-stimulating hormone isoforms in fertility treatment? Reprod Biol Insights 2011; 4:1-10.
19. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12:685-718.
20. Twigt JM, Hammiche F, Sinclair KD, Beckers NG, Visser JA, Lindemans J, et al. Preconception folic acid use modulates estradiol and follicular responses to ovarian stimulation. J Clin Endocrinol Metab 2011; 96: E322-E329.
21. Aittomäki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82:959-968.
22. Mohiyiddeen L, Newman WG, Cerra C, McBurney H, Mulugeta B, Roberts SA, et al. A common Asn680Ser polymorphism in the folliclestimulating hormone receptor gene is not associated with ovarian response to gonadotropin stimulation in patients undergoing in vitro fertilization. Fertil Steril 2013; 99:149-155.
23. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ, Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod 2002; 8:893-899.
24. Sheikhha MH, Eftekhar M, Kalantar SM. Investigating the association between polymorphism of follicle-stimulating hormone receptor gene and ovarian response in controlled ovarian hyperstimulation. J Hum Reprod Sci 2011; 4:86-90.
25. Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwasser P, et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: A pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics 2005; 15:451-456.
26. Morón FJ, Ruiz A. Pharmacogenetics of controlled ovarian hyperstimulation: Time to corroborate the clinical utility of FSH receptor genetic markers. Pharmacogenomics 2010; 11:1613-1618.
27. Pabalan N, Trevisan CM, Peluso C, Jarjanazi H, Christofolini DM, Barbosa CP, Bianco B. Evaluating influence of the genotypes in the folliclestimulating hormone receptor (FSHR) Ser680Asn (rs6166) polymorphism on poor and hyper-responders to ovarian stimulation: A meta-analysis. J Ovarian Res 2014; 7:285.
28. West BE, Parker GE, Savage JJ, Kiratipranon P, Toomey KS, Beach LR, et al. Regulation of the follicle-stimulating hormone beta gene by the LHX3 LIMhomeodomain transcription factor. Endocrinology 2004; 145:4866-4879.
29. Gerli S, Bini V, Favilli A, Di Renzo GC. Clinical efficacy and costeffectiveness of HP-human FSH (Fostimon® ) versus rFSH (Gonal-F® ) in IVF-ICSI cycles: A meta-analysis. Gynecol Endocrinol 2013; 29:520-529.
30. Ulloa-Aguirre A, Timossi C, Barrios-de-Tomasi J, Maldonado A, Nayudu P. Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone: Studies derived from in vitro and in vivo models. Biol Reprod 2003; 69:379-389.